Across the recent three months, 9 analysts have shared their insights on Surgery Partners SGRY, expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 3 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $43.0, a high estimate of $50.00, and a low estimate of $35.00. Highlighting a 2.01% decrease, the current average has fallen from the previous average price target of $43.88.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Surgery Partners by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tao Qiu | Macquarie | Maintains | Outperform | $35.00 | $35.00 |
| A.J. Rice | UBS | Announces | Buy | $38.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $43.00 | $43.00 |
| Bill Sutherland | Benchmark | Maintains | Buy | $50.00 | $50.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $43.00 | $43.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $43.00 | $43.00 |
| Jason Cassorla | Citigroup | Lowers | Buy | $36.00 | $38.00 |
| Bill Sutherland | Benchmark | Maintains | Buy | $50.00 | $50.00 |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $49.00 | $49.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Surgery Partners. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Surgery Partners compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Surgery Partners's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Surgery Partners's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Surgery Partners analyst ratings.
Unveiling the Story Behind Surgery Partners
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
A Deep Dive into Surgery Partners's Financials
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Surgery Partners displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 14.16%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Surgery Partners's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -2.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surgery Partners's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.79%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Surgery Partners's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Surgery Partners's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.76.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
